Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6910882 | 0.92 | TNNI3K (1.00) | TNNI3KBRAF | |
| SCHEMBL6913103 | 0.88 | TNNI3K (0.79) | TNNI3KBRAF | |
| SCHEMBL1804549 | 0.88 | TNNI3K (1.00) | TNNI3KBRAF | |
| SCHEMBL6911672 | 0.88 | TNNI3K (1.00) | TNNI3KBRAF | |
| SCHEMBL1806916 | 0.86 | TNNI3K (1.00) | TNNI3KBRAF | |
| SCHEMBL1807836 | 0.86 | TNNI3K (1.00) | TNNI3KBRAF | |
| SCHEMBL6911370 | 0.85 | TNNI3K (1.00) | TNNI3KBRAF | |
| SCHEMBL12003690 | 0.82 | TNNI3K (1.00) | TNNI3KBRAF | |
| SCHEMBL30104222 | 0.82 | TNNI3K (1.00) | TNNI3KBRAF | |
| SCHEMBL6911341 | 0.82 | TNNI3K (0.71) | TNNI3KBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859571-B2 | Quinazoline compounds | GLAXOSMITHKLINE LLC (US) | 2014-10-14 | — | — | US | claimed |
| EP-2501233-B1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2014-09-24 | — | — | EP | claimed |
| CN-102711474-B | Quinazoline compounds | GLAXOSMITHKLINE LLC | 2014-09-10 | — | — | CN | claimed |
| CN-102711474-A | Quinazoline compounds | GLAXOSMITHKLINE LLC | 2012-10-03 | — | — | CN | claimed |
| US-20120220588-A1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-08-30 | — | — | US | claimed |
| US-8859571-B2 | Quinazoline compounds | GLAXOSMITHKLINE LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859571-B2 | Quinazoline compounds | GLAXOSMITHKLINE LLC (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2501233-B1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2014-09-24 | — | — | EP | disclosed |
| EP-2501233-B1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2014-09-24 | — | — | EP | disclosed |
| CN-102711474-B | Quinazoline compounds | GLAXOSMITHKLINE LLC | 2014-09-10 | — | — | CN | disclosed |
| CN-102711474-A | Quinazoline compounds | GLAXOSMITHKLINE LLC | 2012-10-03 | — | — | CN | disclosed |
| US-20120220588-A1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-08-30 | — | — | US | disclosed |
| US-20120220588-A1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-08-30 | — | — | US | disclosed |
| WO-2011056740-A1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220588-A1 | QUINAZOLINE COMPOUNDS | NQO2, PRMT7, QDPR | TNNI3K 532/4885BRAF 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.